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ETHICAL ISSUES IN CONDUCTING BEHAVIORAL GENETICS
RESEARCH: THE CASE OF SMOKING PREVENTION TRIALS
AMONG ADOLESCENTS*
BENJAMIN S. WILFOND, M.D., GAIL GELLER, Sc.D., CARYN LERMAN, PH.D.,
JANET AUDRAIN-MCGOVERN, PH.D., & ALEXANDRA E. SHIELDS, PH.D.**
I. INTRODUCTION
Despite decades of clinical research and concentrated public health efforts,
smoking remains the leading cause of preventable death in the United States.'
Most adult smokers begin smoking before the age of 18,2 and two-thirds of
adolescents engage in smoking behaviors.3 A substantial proportion of these
adolescents exhibit symptoms consistent with nicotine addiction.4 Thus far, efforts
to prevent smoking and to help adolescents quit smoking have been met with
limited success, 5 leading to the need for broader, trans-disciplinary approaches6 to
* This research was supported by The Robert Wood Johnson Foundation and a Transdisciplinary
Tobacco Use Research Center grant from the National Cancer Institute, the National Institute on Drug
Abuse (P5084718; C.L.). The opinions expressed are those of the authors and do not necessarily reflect
the position or policy of the National Human Genome Research Institute, the National Institutes of
Health, the Public Health Service, or the Department of Health and Human Services.
** Please see biographical information immediately following n. 69. The authors would like to thank
Sarah Gollust, Pat King, Alex Rajczi, and Lainie Ross for their comments on an earlier draft of this
manuscript. In addition, the authors would like to thank Keira Feuner and Jenn Saxman-Tesfaye for
their assistance in preparation and research on this manuscript.
1. J. Michael McGinnis & William H. Foege, Actual Causes of Death in the United States, 270
JAMA 2207, 2207 (1993).
2. OFFICE OF SMOKING AND HEALTH, U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
(DHHS), PREVENTING TOBACCO USE AMONG YOUNG PEOPLE: A REPORT OF THE SURGEON GENERAL,
65 (1994).
3. According to recent studies, 64% of adolescents report ever having smoked cigarettes, 28%
report having smoked on at least one day in the past month, and 14% report having smoked on at least
20 of the last 30 days. Cf Lloyd D. Johnson et al., Monitoring the Future, Nat ' Results on Adolescent
Drug Use: Overview of Key Findings, 2001 NAT'L INST. ON DRUG ABUSE, NIH PUB. NO. 02-5105,
U.S. DHHS (2002); CENTER FOR DISEASE AND CONTROL (CDC), Trends in Cigarette Smoking Among
High School Students-United States, 1991-2001, 51 MORBID. & MORT. WKLY. REP. 409, 409-12
(2002), available at
www.cdc.gov/mmwr/preview/mmwrhtml/rnm51l19al.htm (last visited Nov. 12, 2002).
4. See Warren R. Stanton, DSM-I11-R Tobacco Dependence and Quitting During Late
Adolescence, 20 ADDICT. BEHAV. 595, 598 (1995); Suzanne M. Colby et al., Measuring Nicotine
Dependence Among Youth: A Review of Available Approaches and Instruments, 59 SUPPL. I DRUG &
ALCHOL. DEPEND. S23, S24 (2000).
5. See, e.g., Steve Sussman et al., Effects of Thirty-four Adolescent Tobacco Use Cessation and
Prevention Trials on Regular Users of Tobacco Products, 34 SUBST. USE & MISUSE 1469, 1469 (1999).
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understanding the etiology of smoking behavior and the mechanisms of response to
treatment.
While much has been learned about the socio-environmental and
psychological determinants of adolescent smoking, recent attention has been
devoted to understanding the role of genetic factors. Genes related to
dopaminergic and serotonin pathways, as well as genes related to nicotine
metabolism, contribute to the tendency to smoke and the ability to quit smoking.7
Current research focuses on furthering the understanding of genotype/phenotype
relationships for smoking behavior.8 Studies that address the role of genetics in
smoking behavior in adolescents, but do not provide information on genetic status
to study participants and are ongoing. 9 There also have been proposals to test
adolescents for susceptibility to smoking related health consequences.' 0
Additionally, genetic tests for nicotine dependency are currently being marketed to
parents on the Internet. "
Because of the enthusiasm to prevent and treat adolescent smoking, and the
progress in genetics research, one can anticipate, in the near future, a growing
interest in conducting clinical research that uses genetic information in conjunction
with other strategies to affect smoking behavior, or to select the optimal treatment
and/or prevention interventions for individuals based on their genetic profiles.
12
Such clinical research, whether treatment intervention trials in smokers or
6. Richard R. Clayton et al., Hutchinson Smoking Prevention Project: A New Gold Standard in
Prevention Science Requires New Transdisciplinary Thinking, 92 J. NAT'L CANCER INST. 1964, 1965
(2000).
7. The understanding of the role of genetic factors in smoking behavior and response to treatment
is very tentative at this point, but several large scale, well-designed studies are under way that may
clarify and validate preliminary findings about the relationship between particular polymorphisms and
specific smoking phenotypes. Additional research will be needed to understand the function of these
genetic variants, and the complex interactions between genes, social and environmental factors, as well
as individual personality traits. Caryn Lerman & Wade Berrettini, Elucidating the Role of Genetic
Factors in Cigarette Smoking Behavior and Nicotine Dependence, 2002 AM. J. MED. GENE. 5, 5
(NEURO-PSYCHIATRIc GENETICS) (in press).
8. Id
9. See, e.g., Janet Audrain et al., Recruiting Adolescents into Genetic Studies of Smoking
Behavior, I I CANCER EPIDEMIOL. BIOMARKERS & PREV. 249 (2002).
10. See generally T. Thelin et al., Primary Prevention in a High-Risk Group: Smoking Habits in
Adolescents with Homozygous Alpha-l-Antitrypsin Deficiency (ATD), 85 ACTA. PAEDIATRICS 1207
(1996).
1I. See, e.g., DOC BLUM, Neutraceuticals for the Millennium, available at
http://www.docbluminc.com/smoking.htm (last visited Dec. 17, 2002).
12. One possible strategy, could be to use genetic information to tailor pharmacological smoking
cessation treatment by genotype (i.e., buproprion or transnasal nicotine spray). Another strategy might
be to incorporate information on genetic predisposition to becoming addicted to nicotine or being at
increased risk for smoking related health complications, as part of comprehensive smoking prevention
programs aimed at adolescents who have not yet started smoking; See, e.g., Caryn Lerman et al.,
Pharmacogenetic Investigation of Smoking Cessation Treatment, 12 PHARMACOGENETICS 627 (2002);
see Thelin, supra note 10.
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prevention intervention trials in non-smokers, will raise ethical concerns regarding
the assessment of benefits and risks to participants, particularly because of the
complexity of the association between environmental/genetic factors and behavior,
and the stigmatizing potential of information that may be generated as part of some
of these studies.13
An assessment of the benefits and risks depends, in part, on the type of
participants to be included. A central ethical issue raised by the prospect of
conducting clinical research that involves disclosure of genetic information to
participants is whether these studies should exclude or specifically target
adolescents. 14 While there has been support for involving adolescents in research
related to smoking on ethical grounds, 15 the specific issues related to research that
provides genetic information to participants have not been thoroughly addressed.
There has been a recent shift in federal policy to include "minors" (children and
adolescents) in research (or justify their exclusion) because of the growing
appreciation of a profound lack of data about safety and efficacy of
pharmaceuticals and other interventions in children. 16  In the specific case of
clinical research that incorporates genetic information into smoking intervention
programs, there are two arguments for at least including, if not targeting,
adolescents. 17  One argument, which is only relevant when considering the
involvement of adolescents in smoking prevention trials, is that because the vast
majority of smokers begin smoking in adolescence, targeting smoking prevention
13. The same genes currently associated with smoking behaviors have been associated with other
addictive behaviors, and other behavioral conditions. See, e.g., D.E. Comings et al., Homozygosity at
the Dopamine DRD3 Receptor Gene in Cocaine Dependence, 4 MOLECULAR PSYCHIATRY 484 (1999);
Sachio Matsushita et al., Association Study of Serotonin Transporter Gene Regulatory Region
Polymorphism and Alcoholism, 105 AM. J. MED. GENETICS 446 (2001); Ernest P. Noble, The DRD2
Gene in Psychiatric and Neurological Disorders and its Phenotypes, I PHARMACOGENOMICS 309
(2000).
14. In this paper, we do not mean to distinguish between adolescents and children according to
age. As long as the "minor" is at increased risk of initiating smoking behavior, they would be eligible to
participate in smoking prevention trials, although we might want to set a minimum age (e.g., 10) to
maximize the likelihood of informed assent. Even above the minimum age, the "minor" is likely to have
a different level of involvement in the informed consent process if s/he is 11 -years-old than if s/he is
15-years-old.
15. See, e.g., Eric T. Moolchan & Robin Mermelstein, Research on Tobacco Use Among
Teenagers: Ethical Challenges, 30 J. ADOLESCENT HEALTH 409 (2002)..
16. The National Institutes of Health (NIH) issued a policy requiring the inclusion of children in
"all human subjects research conducted or supported by the NIH," unless there are scientific or ethical
reasons to exclude them. NIH POL'Y AND GUIDELINES ON THE INCLUSION OF CHILDREN AS
PARTICIPANTS IN RES. INVOLVING HUM. SUBJECTS (1998), available at
http://grantsI.nih.gov/grants/guide/notice-files/NOT98-024.html (last visited Nov. 11, 2002). The Food
and Drug Administration (FDA) also encourages pediatric research, by mandating that pharmaceutical
firms include children in studies of all relevant indications. See 21 CFR §§ 201.23, 314.55 (2002). The
FDA also offers six months additional market exclusivity for data pertaining to the use of tested agents
in children. See 21 U.S.C.A. § 355a(b)(I)(A)(i) (2002), and see also Robert Steinbrook, Testing
Medications in Children, 347 N. ENG L. J. MED. 1462, 1462 (2002).
17. See supra note 14.
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studies on adolescents is an efficient, strategic use of public resources and has the
greatest potential to reduce the public health burden of smoking.' 8 The second
argument, which is relevant to either prevention or treatment trials, is that from a
scientific perspective, the physiological, psychological and social characteristics of
adolescents are sufficiently different from those of adults that it may not be
reasonable to generalize from studies of adults to adolescents.19
There are also two main arguments for excluding adolescents from smoking
prevention or intervention trials until there is more information from studies of
adults. The first argument is that, when there is insufficient information about the
likelihood or magnitude of medical and social risks associated with the disclosure
of genetic information to participants, research should initially be conducted in
adults. This concern about exposing children to unknown risks is supported by the
National Commission for the Protection of Human Subjects, which recommended
that research be conducted on adults before it is done in children, when
appropriate, because children are a vulnerable population.2° The concern about the
vulnerability of children as research participants is related to their limited ability to
provide informed consent due to their cognitive and emotional development, level
of autonomy, and dependence on family influence. 21 The vulnerability of children
is particularly important in research that provides genetic information because the
degree of risk, in this case social risk, is unknown. Even in the case of genetic
testing for susceptibility to adult onset disease (as opposed to behavioral traits),
18. Among adults who smoke, 82% first smoked before the age of 18, and 53% became daily
smokers before 18 years of age. See supra note 2 at 65. In this paper, we are not addressing the
possibility of prevention trials for older adults or treatment trials of "minors" because these target
populations do not account for the largest public health burden. Therefore, from the perspective of
public health resources, the impact of such trials is not likely to be worth the investment. See infra note
69 tbl. 1.
19. See generally Ellen A. Skinner et al., Children's Beliefs About Control, Means-Ends, and
Agency: Developmental Differences During Middle Childhood, 11 INT'L. J. BEHAV. DEVEL. 369
(1988); Lawrence D. Cohn et al., Risk Perception: Differences Between Adolescents and Adults, 14
HEALTH PSYCHOL. 217 (1995); John S. Murray, Conducting Psychosocial Research with Children and
Adolescents: A Developmental Perspective, 13 APPL. NURS. RES. 151 (2000).
20. NAT'L COMM'N FOR THE PROTECTION OF HUM. SUBJECTS OF BIOMEDICAL AND BEHAV. RES.,
REPORT AND RECOMMENDATIONS: RES. INVOLVING CHILDREN, PUB. NO. (OS) 77-0004, WASHINGTON,
D.C.: U.S. PRINTING OFFICE 1-2 (1977).
21. Robert J. Levine, Adolescents as Research Subjects Without Permission of Their Parents or
Guardians: Ethical Considerations, 17 J. ADOLESCENT HEALTH 287, 288 (1995); John S. Santelli et al.,
Guidelines for Adolescent Health Research: A Position Paper of the Society for Adolescent Medicine,
17 J. ADOLESC. HEALTH 270, 272 (1995). See generally R.M. Nelson, Children as Research Subjects,
in BEYOND CONSENT: SEEKING JUSTICE IN RESEARCH 47 (J.P. Kahn et al., eds., 1998); Lois A.
Weithom & David G. Scherer, Children's Involvement in Research Participation Decisions:
Psychological Considerations, in CHILDREN AS RESEARCH SUBJECTS: SCIENCE, ETHICS AND LAW 133
(M.A. Grodin & L.H. Glanz eds., 1994).
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where more is known about the relative benefits and risks from studies of adults,
testing of children and adolescents is highly controversial.22
The second argument derives from a larger question, which is relevant to
adults as well, of whether clinical research that uses individual genetic information
to reduce smoking-related morbidity and mortality should be privileged over other
research strategies to influence smoking behavior. According to this argument,
efforts aimed at modifying the social environment experienced by adolescents
should take precedence over genetic-based efforts because such interventions
would potentially benefit all adolescents, not just those identified as having certain
genetic traits and/or involved in interventions. Also, environmental approaches
would not pose the same social risks as those associated with genetic testing for
complex behaviors, such as stigmatization and/or discrimination against teens
identified with specific smoking associated genetic variants.
In this paper, we argue that clinical research that assesses the impact of
genetic information on smoking behaviors should be conducted in adults before it
is conducted in adolescents. While we support the trend of greater inclusion of
children and adolescents in research, at this time, there is insufficient data about
expected benefits to justify the potential risks of involving adolescents in
prevention trials that use information about genetic susceptibility to nicotine
addiction. This paper presents the evidence of limited benefit and potential risks to
adolescents who might participate in such studies, as well as challenges to
adolescents' ability to engage in an informed and voluntary decision-making
process regarding their participation in clinical research that uses genetic
information to influence smoking behavior. We begin with a general discussion of
benefits and risks, and proceed to their specific application in the case of
adolescents. We then review current debates regarding adolescents' capacity to
provide informed consent.
22. Unless genetic tests offer direct medical benefits, the inability of children to provide informed
consent has resulted in a tendency to defer decisions about genetic testing until adulthood. See, e.g.,
ASHG Social Issues Committees, ASHG/ACMG Report, Points to Consider: Ethical, Legal and
Psychosocial Implications of Genetic Testing in Children and Adolescents, 57 AM. J. HUM. GENET.
1233 (1995); Theresa M. Marteau, The Genetic Testing of Children, 31 J. MED. GENET. 743 (1994);
Dorothy C. Wertz et al., Genetic Testing for Children and Adolescents: Who Decides?, 272 JAMA 875
(1994); Ellen Wright Clayton, Removing the Shadow of the Law From the Debate About Genetic
Testing of Children, 57 AM. MED. GENE. 630 (1995); Eric D. Kodish, Testing Children for Cancer
Genes: The Rule of Earliest Onset, 135 J. PEDIATRICS 390 (1999).
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II. ASSESSMENT OF BENEFITS AND RISKS OF ENROLLING ADOLESCENTS IN
PREVENTION TRIALS
A. Questionable Benefit
Any expectation of direct benefit to participants depends on the prior
evidence of a relationship between genes and smoking related outcome/behavior
(clinical validity) and the impact of this information on behavior (clinical utility).23
The evidence for a relationship between genes and smoking behavior includes twin
studies that suggest the proportion of variance in smoking accounted for by
heritable factors ranges from about 50% for smoking initiation to about 70% for
the progression to nicotine dependence.24 Recently, molecular genetic approaches
have been utilized to study genes in the dopamine reward pathway including
receptor genes, transporter genes and metabolism genes. Although some studies
have suggested associations of smoking behavior with genetic variants in the
dopamine pathway,2 5 these findings have not been consistent. 26 Other studies have
linked genes in the serotonin pathway to the likelihood of smoking initiation and
the age at which smoking begins.
27
The potential benefit of utilizing genetic information in clinical research
studies requires consideration of the robustness of these genotype/phenotype
relationships. 28 The understanding of complex genotype/phenotype associations is
tentative, at best, because the necessary studies of the relationship between genes
and behavior are in their infancy. Thus, it is not clear whether genetic information
about smoking behaviors is sufficiently certain to be used in clinical research.
Furthermore, the impact of knowing one's genetic predisposition on behavior
change is unclear. Behavior change could be motivated by the use of information
23. See generally Wylie Burke, Genetic Testing, 347 N. ENGL. J. MED. 1867 (2002).
24. See, e.g., A.C. Heath & N.G. Martin, Genetic Models for the Natural History of Smoking:
Evidence for a Genetic Influence on Smoking Persistence, 18 ADDICT. BEHAV. 19 (1993); Kenneth S.
Kendler et al., A Population-based Twin Study in Women of Smoking Initiation and Nicotine
Dependence, 29 PSYCHOL. MED. 299 (1999); Patrick F. Sullivan & Kenneth S. Kendler, The Genetic
Epidemiology of Smoking, I NICOTINE& TOB. RES. S51 (1999).
25. See, e.g., Sue Z. Sabol et al., A Genetic Association for Cigarette Smoking Behavior, 18
HEALTH PSYCHOL. 7 (1999), available at www.apa.org/journals/hea/heal 817.html (last visited Nov. 17,
2002); Caryn Lerman et al., Evidence Suggesting the Role of Specific Genetic Factors in Cigarette
Smoking, 18 HEALTH PSYCHOL. 14 (1999).
26. See generally Laura Jean Bierut et al., Family-Based Study of the Association of the Dopamine
D2 Receptor Gene (DRD2) with Habitual Smoking, 90 AM. J. MED. GENETICS 299 (2000); Anthony F.
Jorm et al., Association of Smoking and Personality with a Polymorphism of the Dopamine Transporter
Gene: Results from a Community Survey, 96 AM. J. MED. GENETICS 331 (2000).
27. See generally Patrick F. Sullivan et al., Association of the Tryptophan Hydroxylase Gene with
Smoking Initiation but not Progression to Nicotine Dependence, 105 AM. J. MED. GENETICS 479 (2001)
(citing Caryn Lerman et al., Tryptophan Hydroxylase Gene Variant & Smoking Behavior, 105 AM. J.
MED. GENETICS 518 (2001)).
28. Lerman & Berrettini, supra note 7 at 10-11.
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about genes associated with smoking behaviors, or about genes associated with
greater disease susceptibility among individuals who smoke.29 It is possible that
even in the absence of a clear genotype/phenotype association, knowledge that one
has a genotype associated with increased risk of nicotine addiction or lung cancer
may still affect individuals' behavior. Alternatively, even if there is a very strong
relationship between a particular genetic variant and a clinical outcome, disclosure
of the information may not influence behavior. For example, while the association
between alpha-i -antitrypsin deficiency (ATD) and early onset emphysema in
smokers is robust, 30 giving this information to children and their parents has not
resulted in less smoking.
Newborn screening for ATD was conducted in Sweden between 1972-1974.3
However, this study was discontinued because of perceived psychological distress
in parents. 2 The impact of disclosing ATD on smoking behaviors of parents, and
subsequently, on their children is unclear. Most of the studies have not shown a
significant reduction in smoking in the parents or children, while demonstrating
33increased anxiety and distress. Nevertheless, there have been proposals to screen
pre-adolescents for ATD to prevent adolescent smoking.34
There have been a few studies that have examined the impact of genetic
information about smoking-related disease susceptibility on smoking behavior in
29. In addition to genes related to smoking behavior per se, other genes have been identified that
are associated with smoking related morbidity, including the GSTM I polymorphisms and lung cancer
and the alpha lantitrypsin gene and emphysema. See generally Edyta Reszka & Wojciech Wasowicz,
Significance of Genetic Polymorphisms in Glutathione S-Transferase Multigene Family and Lung
Cancer Risk, 14 INT'L. J. OCCUP. MED. ENVTL. HEALTH 99 (2001); Christer Larsson, Natural History
and Life Expectancy in Severe Alpha,- Antitrypsin Deficiency Pi Z 204 ACTA. MED. SCAND. 345
(1978).
30. See generally E. Piitulainen & T. Sveger, Effect of Environmental and Clinical Factors on
Lung Function and Respiratory Symptom in Adolescents with Alphat-Antitrypsin Deficiency, 87 ACTA.
PAEDIATRICS 1120 (1998).
3 1. In this program, 200,000 infants were screened, and 184 of those infants were found to be at
risk of developing early onset emphysema if they smoked or were exposed to smoke or other
respiratory irritants. T. Thelin et al., Identifying Children at High Somatic Risk: Parents' Long-Term
Emotional Adjustment to Their Children's Alpha,-Antitrypsin Deficiency, 72 ACTA. PSYCHIATRY
SCAND. 323, 323 (1985).
32. Id. at 328-329.
33. In a sub-cohort of 61 families, surveyed when the children were between the ages of 5-7,
parents were just as likely to smoke as controls. See Thelin et al., supra note 10 at 1210. A subsequent
follow-up assessment, when these subjects were between the ages of 18-20, indicated that adolescents
with ATD were less likely to smoke (3 of 50 (6%)) compared to controls (8 of 48 (17%)). Id. at 1209.
Two follow-up studies of 50 of these children, between 16 and 18 years of age, did not show any
difference in the smoking rates of the adolescents or parents compared to controls. T. Sveger et al.,
Lung Function in Adolescents with Alphal-Atitrypsin Deficiency, 83 ACTA. PAEDIATRICS 1170, 1173
(1994). See also, T. Sveger et al., Clinical Features and Lung Function in 18-year-old Adolescents with
Alphai-Antitrypsin Deficiency, 84 ACTA. PAEDIATRICS 815, 815-16 (1995). Further, in another report
of a larger cohort of this ATD population, 13 of 128 (10%) currently smoked. See Piitulainen & T.
Sveger, supra note 30 at 1123.
34. See generally Thelin et al., supra note 10.
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adults. Lerman and colleagues conducted a randomized trial to assess the impact
of feedback on genetic susceptibility to lung cancer related to the CYP2D6
polymorphism. 35 Although the information produced positive changes in smoking-
related beliefs and motivations, there were no significant differences in smoking
quit rates after two or twelve months.36 There was evidence for a small increase in
depression symptoms that was not maintained at follow-up. In another randomized
study, African-American smokers were recruited through a community clinic and
offered a blood test for the GST3 gene (GSTM1) to determine susceptibility to
tobacco-related cancers.37 Eighty-three percent of the participants agreed to have a
blood test for GSTM1. 38 At six months, smoking cessation was greater in
participants offered the test (19% vs. 10%), but at twelve months the smoking
cessation rates were comparable.39
In contexts other than smoking, genetic information has been shown to limit
impact on behavior in adolescents. While dietary interventions are effective in
maintaining phenylalanine levels in an acceptable range to avoid neurocognitive
effects in people with Phenylketonuria (PKU), adolescents do not always stay on
the diet. In a recent study from the United Kingdom, approximately 70% of
children younger than 10 years old were able to keep their phenylalanine levels in
the acceptable range through diet range, but this decreased to approximately 20%
for adolescents over the age of 15.40 This illustrates the limitations of using
personalized feedback about risk in adolescents to change their behavior in order to
avoid adverse health consequences.
In light of the current data, there is a low likelihood of benefit to adolescents
who participate in studies that involve the disclosure of participants' genotype for
two reasons. First, there is a limited understanding of the genes associated with
smoking related behaviors or the health consequences of smoking. Second,
available data from other contexts suggests that relaying information about one's
genetic risks rarely leads to significant behavioral change.
35. See generally Caryn Lerman et al., Incorporating Biomarkers of Exposure and Genetic
Susceptibility into Smoking Cessation Treatment: Effects on Smoking-Related Cognitions, Emotions,
and Behavior Change, 16 HEALTH PSYCHOLOGY 87 (1997).
36. Id.; see also Janet Audrain et al., Genetic Susceptibility Testing in Smoking-Cessation
Treatment: One- Year Outcomes of a Randomized Trial, 22 ADDICT. BEHAv. 741, 741-42 (1997).
37. Colleen M. McBride et al., Incorporating Genetic Susceptibility Feedback into a Smoking
Cessation Program for African-American Smokers with Low Income, 11 CANCER EPIDEMIOL.
BIOMARKERS & PREV. 521, 522 (2002).
38. Id.
39. Id.
40. See J.H. Walter et al., How Practical are Recommendations for Dietary Control in
Phenylketonuria?, 360 LANCET 55, 55 (2002).
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B. Potential risks
While the issue of harm to individuals from disclosure of genetic information
is not new, and has been previously addressed in several other contexts, 41 what
may be important in the case of genes associated with smoking behavior is the
extent to which the conditions and behaviors involved are socially sensitive and
engage notions of personal responsibility.42 Genes involved in dopamine and
serotonin regulation, which have been a primary focus of research, have also been
associated with risk for substance abuse more generally, including addiction to
cocaine, addiction to alcohol use,43 and a number of psychiatric conditions (e.g.,
Tourettes Syndrome,44  Anxiety,4 5  Attention Deficit Hyperactive Disorder
(ADHD),4 6  Post-traumatic Stress Disorder (PTSD), 47 Obsessive-Compulsive
Disorder (OCD), 48 depression, and suicide49). Genetic information relating to
41. See, e.g., Judith L. Benkendorf et al., Patients' Attitudes About Autonomy and Confidentiality
in Genetic Testing for Breast-Ovarian Cancer Susceptibility, 73 AM. J. MED. GENE. 296 (1997); see
also Jeffrey R. Botkin, Protecting the Privacy of Family Members in Survey and Pedigree Research,
285 JAMA 207 (2001); Gary N. McAbee & Jack Sherman, Physician's Duty to Warn Third Parties
About the Risk of Genetic Diseases, 102 PEDIATRICS 140, 141-42 (1998).
42. Charles P. O'Brien & A. Thomas McLellan, Myths About the Treatment of Addiction, 347
LANCET 237, 237 (1996); see also A. Thomas McLellan et al., Drug Dependence, a Chronic Medical
Illness: Implications for Treatment, Insurance, and Outcomes Evaluation, 284 JAMA 1689, 1690
(2000).
43. See, e.g., Kenneth Blum et al., Allelic Association of Human Dopamine D 2 Receptor Gene in
Alcoholism, 263 JAMA 2055 (1990); Noble, supra note 13; Comings et al., supra note 13; Dirk
Lichtermann et al., Support for Allelic Association of a Polymorphic Site in the Promoter Region of the
Serotonin Transporter Gene with Risk for Alcohol Dependence, 157 AM. J. PSYCHIATRY 2045 (2000);
Matsushita et al., supra note 13.
44. D.E. Comings et al., Studies of the Potential Role of the Dopamine D, Receptor Gene in
Addictive Behaviors, 2 MOLECULAR PSYCHIATRY 44, 44 (1997) (citing Kenneth Blum et al., Dopamine
D2 Receptor Gene Radiants: Association and Linkage Studies in Impulsive, Addictive and Compulsive
Disorders, 5 PHARMACOGENETICS 121 (1995)).
45. See generally Klaus-Peter Lesch et al., Association of Anxiety-Related Traits with a
Polymorphism in the Serotonin Transporter Gene Regulatory Region, 274 SCI. 1527 (1996).
46. D.E. Comings et al., Dopamine D2 Receptor (DRD2) Gene and Susceptibility to Posttraumatic
Stress Disorder: A Study and Replication, 40 BIO. PSYCHIATRY 368, 368 (1996) (citing D. E. Comings
et al., The Dopamine D2 Receptor Locus as a Modifying Gene in Neuropsychiatric Disorders, 266
JAMA 1793 (1991)); see also Pierandrea Muglia et al., Adult Attention Deficit Hyperactivity Disorder
and the Dopamine D4 Receptor Gene, 96 AM. J. MED. GENE 273, 274 (2000).
47. See Comings et al., supra note 44 at 368.
48. David C. Rowe et al., The Relation of the Dopamine Transporter Gene (DA TI) to Symptoms of
Internalizing Disorders in Children, 28 BEHAV. GENE. 215, 215 (1998).
49. David A. Nielson et al., A Tryptohan Hydroxylase Gene Marker for Sucidiality and
Alcoholism, 55 ARCH. GEN. PSYCHIATRY 593, 593-95 (1998); see Frank Bellivier et al., Serotonin
Transporter Gene Polymorphisms in Patients with Unipolar or Bipolar Depression, 255
NEUROSCIENCE LETTERS 143, 143 (1998) (citing A.D. Ogilvie et al., Polymorphism in Serotonin
Transporter Gene Associated with Susceptibility to Major Depression, 347 LANCET 731 (1996)).
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behaviors such as substance abuse and psychiatric disorders may be far more
stigmatizing to individuals relative to stigma associated with smoking. 50
The range of pleiotropic associations of smoking-related genes may also lead
to greater risk of discrimination in future employment or health insurance
contexts. 51 Current smokers already face significant problems with insurance,
employment, and social stigmatization.52 This group might be particularly
vulnerable to further discrimination. 53  However, because smokers already face
substantial social discrimination, additional problems related to genetic
information may not be so significant. It is possible too that some might view
genetic information as a mitigating factor to explain smokers' addiction to
nicotine. However, because these pleiotropic associations are tentative, and the
role of these genes in the behavior of addiction is not clear, it will be difficult to
estimate the likelihood and magnitude of the potential harms related with such
associations. While the meaning of these identified genotype-phenotype
relationships have yet to be fully understood, it seems likely that there would be
additional risks for participants in studies that provide information about genotypes
with potentially stigmatizing pleiotropic associations in contrast to studies that
provide information about risk for health consequences of smoking that do not also
have additional genetic associations.
There may be specific risks of involving adolescents in research that discloses
genetic risks related to smoking. "Labeling" adolescents, as being at risk for
addiction or at risk for health complications of smoking, may be particularly
damaging to their self-image and their view of their ability to shape their future.54
There may also be an adverse impact of this information on smoking behavior per
50. See generally M.R.B. Davies, The Stigma of Anxiety Disorders, 54 INT'L. J. CLIN. PRAC. 44
(2000); Bruce G. Link et al., On Stigma and Its Consequences: Evidence from a Longitudinal Study of
Men with Dual Diagnoses of Mental Illness and Substance Abuse, 38 J. HEALTH & Soc. BEHAV. 177
(1997) [hereinafter Bruce G. Link et al. On Stigma]; Bruce G. Link et al., Public Conceptions of
Mental Illness: Labels, Causes, Dangerousness, and Social Distance, 89 AM. J. PUB. HEALTH 1328
(1999) [hereinafter Bruce G. Link et al. Public Conceptions]; Jo C. Phelan et al., Psychiatric Illness
and Family Stigma, 24 SCHIZOPHRENIA BULL. 115 (1998); E.B. Ritson, Alcohol, Drugs and Stigma, 53
INT'L. J. CLIN. PRAC. 549 (1999).
5 1. See generally Kathy L. Hudson et al., Genetics Discrimination and Health Insurance: An
Urgent Need for Reform, 270 SC. 391 (1995).
52. See generally Scott Burris, Disease Stigma in U.S. Public Health Law, 30 J. L. MED. &
ETHICS 179 (2002).
53. It is unknown to what extent additional plieotropic associations of smoking-related genes
might exacerbate the potential for discrimination against individuals identified having particular risk-
conferring alleles. For example, one could imagine that self-insured employers might more likely
discriminate against such persons based on a higher health care costs associated with substance abuse
and mental health. See generally Deborah W. Gamick et al., Do Individuals with Substance Abuse
Diagnoses Incur Higher Charges than Individuals with Other Chronic Conditions?, 14 J. OF
SUBSTANCE ABUSE TREATMENT 457 (1997).
54. See Skinner et al., D. Cohn et al., and Murray, supra note 19.
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se due to confusion about the meaning of genetic information. Adolescents who
are told that they have a genotype associated with a reduced likelihood of an
adverse health outcome from smoking might be resistant to public health messages
about the risks of smoking and more willing to smoke. Adolescents who are told
that they do not have a particular genotype associated with an increased risk of
nicotine addiction, for example, may erroneously believe that they can smoke
without developing a habit. Adolescents who already smoke who are told that they
possess a genotype associated with increased risk of nicotine addiction might
conclude that it is not worth trying to quit. Thus, providing genetic information to
adolescents to positively motivate behavior might turn out to have adverse
psychological effects, and might even inadvertently promote smoking behavior.
C. Balancing Benefits and Risks
In research involving children, federal regulations require that the "prospect
of direct benefit" must justify the risks.55 Such risk/benefit assessments are
inherently subjective but critical, nonetheless. One operational use of this
assessment is in choosing between alternative study designs. The evaluation of
risks and benefits can be done comparatively. Given a specific amount of risk
posed by a particular study, for example, one should choose the design with the
greatest benefits to participants. Similarly, if the anticipated benefits to participants
are fixed, one should select the design that poses the least risk to study participants.
This approach can be useful in deciding which studies to conduct initially, and may
be particularly relevant to initial studies about the impact of genetic information on
smoking behavior, since there is great uncertainty about the likelihood of risks and
potential benefits.
There may be a more favorable risk/benefit ratio for studies that target
smokers than nonsmokers. The potential direct benefits to smokers are arguably
greater (even though the public health benefit of prevention is more profound)
since they are currently engaged in a behavior with substantial health risks.
Additionally, the harms may be more significant in studies that use genetic
information to prevent smoking than studies that would use such information to
facilitate quitting. First the potential population for preventive interventions is
much larger (i.e., all at risk individuals), so the impact of any risks would create a
greater public health concern. Further, while risks of stigmatization might occur in
both smokers and nonsmokers, the concerns about discrimination may be less
salient for smokers who already face significant discrimination.
Given that, comparatively speaking, the risks are lower to smokers and to
adults, we argue that the first studies in which genetic status is communicated to
participants should be conducted with adult smokers recruited into treatment trials.
Such studies will provide important data on the impact of genetic information on
55. 45 C.F.R. §46.405 (2001).
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smoking behavior, the possibility of achieving improved quit rates through
genetically tailored treatments, and the possible unintended adverse effects
associated with this genetic information among adults. Only after such studies
have provided greater clarity about anticipated benefits and risks experienced by
adult smokers would we support the initiation of prevention trials. Initial
prevention studies should be conducted in young adults between the ages of 18-25,
recruited through community or college-based programs. Members of this age
group are old enough to make their own decisions, but young enough to still be at
risk to begin smoking. Only once such studies are completed with an acceptable
risk/benefit profile, should preventions studies be conducted in minors. Even then,
prevention trials in minors should initially focus on assessing genes associated
with health-related consequences of smoking (e.g. alpha-l-antitrypsin), before
assessing genes associated with smoking behavior since the former may have
fewer risks than the latter.
III. THREATS TO INFORMED AND VOLUNTARY DECISION-MAKING
In addition to concerns about the benefits and risks of enrolling adolescents in
research that provides genetic information, there are concerns about their ability to
engage in a valid and meaningful informed consent process. There are two main
threats to the ability of adolescents to engage in informed and voluntary decision-
making. Although both of these concerns apply when adolescents are enrolled in
any kind of research, there are some unique aspects of these concerns in the
specific case of behavioral genetics intervention trials.
First, there may be general worries that adolescents may not have the ability
to appreciate the risks of the research and may be more vulnerable to undue
influences to enroll in research. There have been several empirical studies that
have focused on the impact of developmental changes on decision-making56 and
the effect variation in psychological states may have on children's ability to assess
risks associated with research participation. 57 Evidence suggests that most children
younger than 9-years-old cannot be expected to consent or assent to clinical
research in a meaningful way.58 However, most adolescents, at least past the ages
of 14 or 15, are able to function as well as adult research participants under most
circumstances. 59 Based on this evidence alone, one can argue that it is morally
56. See Skinner et al., Cohn et al., and Murray supra note 19.
57. See, e.g., Lorah D. Dorn et al., Informed Consent in Children and Adolescents: Age,
Maturation and Psychological State, 16 J. ADOLESC. HEALTH 185 (1995).
58. Nancy Ondrusek et al., Empirical Examination of the Ability of Children to Consent to Clinical
Research, 24 J. MED. ETHICS 158, 158 (1998).
59. Society for Adolescent Medicine, Guidelines for Adolescent Health Research, 17 J. ADOLESC.
HEALTH 270, 272 (1995); see also Anne C. Petersen & Nancy Leffert, Developmental Issues
Influencing Guidelines for Adolescent Health Research: A Review, 17 J. ADOLESC. HEALTH 298, 299
(1995).
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justifiable to include adolescents in clinical research that assesses the impact of
genetic information on smoking behavior. However, this evidence is derived from
studies that have been limited to populations of unhealthy children who were
participants in clinical/therapeutic research6 ° or psychosocial research.6' Less is
known about how healthy children, who may be at increased risk for inherited
susceptibility to nicotine addiction or the health consequences of smoking, will
assess benefits and risks. Further research is needed in this area in order to guide
decisions of Institutional Review Boards and others evaluating genetic
susceptibility studies of healthy children.
A second concern is the degree to which adolescents will be subjected to
undue influences from parents, the researchers, or other social contacts, including
friends, teachers or health care practitioners. This is particularly true when
research may offer a prospect of direct benefit, parents may be more inclined to
pressure adolescents to participate. It is imperative to give careful consideration to
the circumstances under which adolescents would be recruited for research on
genetics and smoking. Although evidence suggests that adolescents are more
likely to be involved in informed consent discussions than younger children, and
their opinions are given more weight because of greater cognitive and emotional
62
capacity, they are still highly impressionable. The potential for undue influence
by others is a risk in any research involving minors. However, the degree to which
there is an added risk in behavioral genetics research turns on whether genetic test
results will be disclosed to the participants as part of the research.
The recruitment experience in a longitudinal cohort study to evaluate the
genetic, psychological and social contributions to adolescent smoking63 did not
suggest that participants were unduly influenced to enroll. In this study,
adolescents were recruited after first getting parental permission and only 54% of
parents gave their permission. Lack of interest in the goals of the project was the
most commonly cited reason for parents declining (4 7 %).64 Parents were almost
60. Gail Geller et al., Informed Consent for Enrolling Minors in Genetic Susceptibility Research:
A Qualitative Study of At-Risk Children's and Parents' Views about the Role Children Should Play in
Decision-Making, J. ADOLES. HEALTH (in press) (citing generally Susan Michie et al., Predictive
Genetic Testing in Children and Adults: A Study of Emotional Impact, 38 J. MED. GENE. 519 (2001);
Marion Broome et al., Children in Research: The Experience of Ill Children and Adolescents, 7 J. FAM.
NURS. 32, 32-33 (2001); E.J. Susman et al., Participation in Biomedical Research: The Consent
Process as Viewed by Children, Adolescents, Young Adults, and Physicians, 121 J. PEDS. 547 (1992);
Marion E. Broome, Consent (Assent) for Research with Pediatric Patients, 15 SEMINARS IN ONC.
NURS. 96 (1999)).
61. Id. (citing generally Sue Miller, Researching Children: Issues Arising from a
Phenomenological Study with Children Who Have Diabetes Mellitus, 31 J. ADV. NURS. 1228 (2000);
Michael Rich et al., Video Intervention/Prevention Assessment: A Patient-Centered Methodology for
Understanding the Adolescent Illness Experience, 27 J. ADOLESC. HEALTH 155 (2000)).
62. Id. at 19-20.
63. See generally Audrain et al., supra note 9.
64. Audrian et al., supra note 9 at 251-52. Concerns about confidentiality were expressed by 16%
of declining parents. Almost half of these parents raised specific concerns about genetics, and the rest
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three times more likely to attribute this lack of interest to the adolescents rather
than to themselves.65 This suggests that family members discussed the project with
one another prior to making their decision and that parents generally respected the
decisions of their teenagers regarding participation. However, genetic test results
were not disclosed as part of this study.
Other studies also have demonstrated the tendency of parents to defer to their
adolescent children regarding decisions about participation in "nontherapeutic"
research. However, in studies that offer potential benefit to teenage participants,
parents are more likely to encourage their children to participate (or override their
children's refusal).66 Studies that offer the results of genetic testing and/or the
opportunity to participate in a preventive intervention might be perceived by
parents as having potential benefits for their adolescents. 67  Moreover, genetic
information about adolescents has potential relevance for the parents themselves.
To the degree that parents derive some personal benefit from learning about their
own susceptibility to nicotine addiction or to adverse health consequences of
smoking, and perceive a potential benefit to enrolling their adolescents in
prevention or treatment trials, they might be more likely to "coerce" their
adolescents into participating in such research.68 Because of concern about undue
influences on adolescent decision-making, particularly when the benefits do not
justify the potential risks, we believe that minors should be excluded from initial
studies.
IV. CONCLUSION
Clinical studies that use genetic information to influence smoking behavior
among adolescents are seductive because they may lead to important new tools to
address a seemingly intractable public health problem. However, because of an
uncertain and potentially less favorable risk/benefit ratio and limitations of
adolescent authority to make informed and voluntary decisions, initial studies that
use genetic information to influence smoking behavior should not target
adolescents.69 Only once there is additional information about the empirical
reflected nonspecific concerns over data privacy. Confidentiality regarding adolescent genetic testing
was less of a concern, perhaps because this study did not provide the adolescents with their genetic test
results.
65. Audrian et al., supra note 9 at 252.
66. See generally Gail Geller et al., Mothers and Daughters from Breast Cancer Families: A
Qualitative Study of their Perceptions of the Risks and Benefits Associated with Minors' Participation
in Genetic Susceptibility Research, 55 JAMWA 280 (2000); Barbara A. Bernhardt et al., Parents' and
Children 's Attitudes Toward the Enrollment of Minors in Genetic Susceptibility Research: Implications
for Informed Consent, 2002 AM. J. MED. GENETICS DRAFT I (in press).
67. Geller et al., supra note 66 at 282, 283; Bernhardt et al., supra note 66 at 17-20.
68. Bernhardt et al., supra note 66 at 22.
69. Table I provides a graphical representation of the phased-in approach proposed in this article.
See supra note 14 and accompanying text.
[VOL. 6:73
2002] ETHICAL ISSUES IN CONDUCTING BEHAVIORAL GENETICS RESEARCH 87
benefits and risks of providing such information in the context of treatment trials
for adult smokers should prevention studies be conducted. These prevention trials
should first be conducted in young adults between the age of 18 and 25 before
enrolling minor adolescents. Additionally, prevention trials in adolescents should
Tb! 1: Phased-in Approach to Research on Genetics & Smoking-Related Behaviors
Type of Research Age of Target Phase 1 Phase 2 Phase 3
(population) Population
Treatment Trials
(smokers) Adults (> 18) 0
Prevention Trials Young Adults 0
(nonsmokers) (18-25)
Minors (10-17) 0
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first provide information related to the health consequences of smoking compared
to studies that provide information about smoking related behaviors.
While we acknowledge that this "phased-in" approach will slow down the
integration of clinical approaches based on genetic information, we believe such
caution is warranted. Until there is sufficient evidence that genetic-based smoking
prevention and treatment interventions can play an important role in improving
public health among adults, there is no justification for exposing adolescent
participants to unnecessary risks.
